Clinical Trials Browser

Not yet recruiting × Primary Myelofibrosis × 30 days × Clear all

Anemia, Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Splenomegaly, Bone Marrow Neoplasms, Primary Myelofibrosis

NCT07539779 2026-04-20

Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis

Phase 2/3 Not yet recruiting

196 enrolled

MyeloidOther hematologic neoplasm

Hematologic Neoplasms, Primary Myelofibrosis

NCT07302776 2026-04-17

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

Phase 1 Not yet recruiting

50 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT07527221 2026-04-14

Safety and Tolerability of ZE74-0282 in Healthy Volunteers

Phase 1 Not yet recruiting

40 enrolled

MyeloidOther hematologic neoplasm

Polycythemia, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT07529951 2026-04-14

Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers

Phase 1 Not yet recruiting

60 enrolled

Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT07518940 2026-04-09

ENERGIA

Phase NA Not yet recruiting

25 enrolled

MyeloidOther hematologic neoplasm

Motor Activity, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

Clinical Trials

Therapeutic RSK1 Targeting in Myelofibrosis

Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

Safety and Tolerability of ZE74-0282 in Healthy Volunteers

Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers

ENERGIA